Leukine sargramostim: Phase III; marketed for cancer

IMNX said that its GM-CSF was able to reduce viral load in combination with Glaxo Wellcome's Retrovir zidovudine

Read the full 182 word article

How to gain access

Continue reading with a
two-week free trial.